Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| dry eye disease patients and generate substantial value for Harrow stockholders over a very long period |
| We feel that's strongly intact |
| And together, we're going to build a company that we can be proud of |
| Number one, we achieved record revenues with 2023 revenues increasing 47% over 2022 revenues |
| And in terms of what the size of the market can be, this is a product that gives me far greater confidence that the number that I wrote about a couple of letters to stockholders ago, which was $1 billion in revenue in the aggregate for our product portfolio that can actually be met |
| Importantly, the product is performing extremely well |
| What I can tell you is that we're getting very strong help from our manufacturing partner, and our manufacturing partner as you can see on the box for the product is a very sophisticated organization |
| And finally, delivering $8.7 million in cash from operating activities in the fourth quarter of last year and delivering our second consecutive year of positive cash flow from operations |
| I mentioned the news that we received from CMS yesterday, which is going to make IHEEZO, which is our low viscosity patented topical anesthetic gel, which is doing fantastic things in clinics and surgery centers across the country |
| It's also obviously used in numerous other ophthalmic interventions, and it's a very, very exciting opportunity for us |
| It kind of hit us with a very, very positive surprise |
| So look, we're standing behind the better than $180 million in revenue guidance that we put out for 2024 |
| This detailed information highlights, among other things, the amazing success we've had with our VEVYE launch |
| I say this because of the amazing progress we made in 2023, and because of what is right in front of us, right in front of our eyes, a clear pathway to achieving our goals, including significant revenue and profitability growth, ultimately making us a leading strategic North American ophthalmic pharmaceutical company |
| It's a beautiful thing for many reasons because we're seeing amazing stories, practical stories of how IHEEZO is positively changing anesthesia protocols around the country for ophthalmic procedures |
| Our team feels very good about what we believe is going to happen to IHEEZO and therefore Harrow |
| And the effort that she has put into this project is just amazing |
| But as you saw in our recent corporate presentation, all of the numbers, all of the metrics with respect to the VEVYE launch are up into the right, which is fantastic |
| But what I can tell you is that the progress that we've made in the last six months in particular has given everyone in our organization a very high degree of confidence that we're going to have success meeting all of the required parameters to make Triesence here very soon |
| Mark by word, VEVYE will significantly benefit millions of U.S |
| But IHEEZO is a fantastic product for that application |
| But it certainly gives us far greater confidence in our guidance |
| Based on our success to date, I am convinced that VEVYE has the potential to dominate the large U.S |
| But we're very excited about what we put out today in the Form 8-K |
| In fact, three times in the past 12 months, precisely because I believe in Harrow's long-term value and because the shares have been available at an attractive price |
| They want to know why we're so bullish on our company and the growth trajectory we see in front of us |
| It certainly supports our confidence in our guidance, which is a number greater than $180 million |
| So we're really excited about that and what Maria and her amazing team are doing with VEVYE |
| Now we've got this great outcome with CMS |
| You see we strengthened our balance sheet last year, especially our cash position, ending the year with $83 million in cash and cash equivalents, and this includes our position in pharmaceuticals |
| Statement |
|---|
| And this has affected our sales temporarily in the first quarter, but we are seeing evidence of the systems beginning to be unclogged |
| We knew that it was going to be a challenge, reintroducing the product into the market in terms of manufacturing it |
| But this is an issue, the cyber-attack that has affected us, but it has affected many, many companies who sell into the pharma market |
| And so one of the challenges is with a product that on the FDA's drug shortage list that's not being made -- that has not been priced competitively |
| There were people in our organization, by the way, that were somewhat doubtful |
| It's an unusual product with an unusual label |
| So the issue with Change Healthcare has affected numerous companies, including us, that sell not only Part D as in David products, but also Part B is and Bravo products |
| I also want to mention that it's never been a better time to be a Harrow stockholder |
| And so we're going to kind of temper revenue growth with EBITDA expectations |
| So the system is still sort of being unclogged |
| Harrow's results may differ materially from those projected |
| Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies, and FDA approval of certain drug candidates in a timely manner or at all |
| And the Change Healthcare issue has affected payments to our customers from the government |
Please consider a small donation if you think this website provides you with relevant information